

# Javier A Menendez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1788867/publications.pdf>

Version: 2024-02-01

337  
papers

27,143  
citations

9254

74  
h-index

7340

152  
g-index

345  
all docs

345  
docs citations

345  
times ranked

42308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
3	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. <i>Nature Reviews Cancer</i> , 2007, 7, 763-777.	12.8	2,355
4	Olive oil and health: Summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 284-294.	1.1	449
5	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10715-10720.	3.3	297
6	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018, 24, 1024-1035.	15.2	285
7	Metformin: Multi-faceted protection against cancer. <i>Oncotarget</i> , 2011, 2, 896-917.	0.8	263
8	Autophagy in stem cells. <i>Autophagy</i> , 2013, 9, 830-849.	4.3	255
9	The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. <i>Cell Cycle</i> , 2009, 8, 88-96.	1.3	238
10	Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab. <i>PLoS ONE</i> , 2009, 4, e6251.	1.1	206
11	Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. <i>Cell Cycle</i> , 2010, 9, 1057-1064.	1.3	205
12	Metformin against TGF $\beta$ -induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. <i>Cell Cycle</i> , 2010, 9, 4461-4468.	1.3	202
13	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin $\text{®}$ ) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005, 16, 359-371.	0.6	197
14	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1001-1016.	1.5	185
15	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010, 9, 3831-3838.	1.3	179
16	Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer. <i>Clinical Chemistry</i> , 2009, 55, 425-438.	1.5	175
17	The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 355-364.	1.1	173
18	Autophagy positively regulates the CD44 <sup>+</sup> CD24 <sup>-</sup> breast cancer stem-like phenotype. <i>Cell Cycle</i> , 2011, 10, 3871-3885.	1.3	172

#	ARTICLE	IF	CITATIONS
19	Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin. <i>PLoS ONE</i> , 2013, 8, e77281.	1.1	171
20	Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 483-494.	0.9	163
21	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <i>Cell Proliferation</i> , 2008, 41, 59-85.	2.4	160
22	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin <sup>®</sup> ) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007, 7, 80.	1.1	154
23	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. <i>Cell Cycle</i> , 2013, 12, 1166-1179.	1.3	146
24	Antitumoral actions of the anti-obesity drug orlistat (Xenical <sup>®</sup> ) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. <i>Annals of Oncology</i> , 2005, 16, 1253-1267.	0.6	144
25	A novel CYR61-triggered $\alpha$ -CYR61- $\beta$ 3 integrin loop <sup>TM</sup> regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. <i>Oncogene</i> , 2005, 24, 761-779.	2.6	138
26	Metformin-induced preferential killing of breast cancer initiating CD44 <sup>+</sup> CD24 <sup>~</sup> /low cells is sufficient to overcome primary resistance to trastuzumab in HER2 <sup>+</sup> human breast cancer xenografts. <i>Oncotarget</i> , 2012, 3, 395-398.	0.8	134
27	Characterization and quantification of phenolic compounds of extra-virgin olive oils with anticancer properties by a rapid and resolute LC-ESI-TOF MS method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 416-429.	1.4	132
28	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging. <i>Cell Cycle</i> , 2011, 10, 3658-3677.	1.3	132
29	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. <i>Cell Cycle</i> , 2013, 12, 555-578.	1.3	131
30	Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 381-391.	1.2	126
31	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. <i>European Journal of Cancer</i> , 2001, 37, 402-413.	1.3	124
32	Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 540-546.	3.4	124
33	Synergism of plant-derived polyphenols in adipogenesis: Perspectives and implications. <i>Phytomedicine</i> , 2012, 19, 253-261.	2.3	122
34	Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 643-654.	1.9	119
35	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). <i>Cell Cycle</i> , 2012, 11, 4020-4032.	1.3	119
36	Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 894-899.	1.1	117

#	ARTICLE	IF	CITATIONS
37	Metformin is synthetically lethal with glucose withdrawal in cancer cells. <i>Cell Cycle</i> , 2012, 11, 2782-2792.	1.3	116
38	Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	1.4	116
39	Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018. <i>Nutrients</i> , 2019, 11, 2039.	1.7	116
40	Anti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). <i>BMC Cancer</i> , 2008, 8, 377.	1.1	108
41	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGF $\beta$ 2-induced oncomiR miRNA-181a. <i>Cell Cycle</i> , 2011, 10, 1144-1151.	1.3	108
42	Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway. <i>Methods in Molecular Biology</i> , 2014, 1170, 113-144.	0.4	108
43	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. <i>Cell Cycle</i> , 2010, 9, 3807-14.	1.3	107
44	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. <i>Aging</i> , 2012, 4, 480-498.	1.4	104
45	Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness. <i>Aging</i> , 2012, 4, 393-401.	1.4	104
46	The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.. <i>Endocrine-Related Cancer</i> , 2003, 10, 141-152.	1.6	103
47	Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?. <i>Endocrinology</i> , 2006, 147, 4056-4066.	1.4	102
48	Mapping Protein-Protein Interactions for the Yeast ABC Transporter Ycf1p by Integrated Split-Ubiquitin Membrane Yeast Two-Hybrid Analysis. <i>Molecular Cell</i> , 2007, 26, 15-25.	4.5	102
49	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. <i>International Journal of Cancer</i> , 2005, 115, 19-35.	2.3	100
50	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. <i>Aging</i> , 2020, 12, 8-34.	1.4	99
51	A genomic explanation connecting the Mediterranean diet, olive oil and cancer: Oleic acid, the main monounsaturated Fatty acid of olive oil, induces formation of inhibitory PEA3 transcription factor-PEA3 DNA binding site complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. <i>European Journal of Cancer</i> , 2006, 42, 2425-2432.	1.3	98
52	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 471-479.	1.1	98
53	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. <i>Scientific Reports</i> , 2013, 3, 2469.	1.6	97
54	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007, 20, 3-10.	1.8	96

#	ARTICLE	IF	CITATIONS
55	Metabostemness: A New Cancer Hallmark. <i>Frontiers in Oncology</i> , 2014, 4, 262.	1.3	95
56	The active form of the metabolic sensor AMP-activated protein kinase $\hat{\pm}$ (AMPK $\hat{\pm}$ ) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. <i>Cell Cycle</i> , 2009, 8, 2385-2398.	1.3	94
57	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. <i>Cell Cycle</i> , 2012, 11, 974-989.	1.3	94
58	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. <i>Oncotarget</i> , 2014, 5, 8306-8316.	0.8	94
59	$\hat{\pm}$ $\hat{\nu}$ <sup>23</sup> integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. <i>Oncogene</i> , 2005, 24, 3759-3773.	2.6	93
60	Mediterranean diet, olive oil and cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 15-21.	1.2	93
61	Direct characterization of aqueous extract of <i>Hibiscus sabdariffa</i> using HPLC with diode array detection coupled to ESI and ion trap MS. <i>Journal of Separation Science</i> , 2009, 32, 3441-3448.	1.3	93
62	Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. <i>Oncology Reports</i> , 2008, 20, 1369-74.	1.2	92
63	Polyphenols and the Modulation of Gene Expression Pathways: Can We Eat Our Way Out of the Danger of Chronic Disease?. <i>Critical Reviews in Food Science and Nutrition</i> , 2014, 54, 985-1001.	5.4	91
64	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. <i>Cell Cycle</i> , 2013, 12, 3109-3124.	1.3	90
65	Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9). <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 495-502.	0.9	88
66	Targeting STAT3 with silibinin to improve cancer therapeutics. <i>Cancer Treatment Reviews</i> , 2017, 58, 61-69.	3.4	86
67	Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. <i>Oncogene</i> , 2018, 37, 963-970.	2.6	85
68	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. <i>Frontiers in Endocrinology</i> , 2018, 9, 657.	1.5	85
69	Exogenous supplementation with $\hat{\nu}$ -3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. <i>European Journal of Cancer Prevention</i> , 2005, 14, 263-270.	0.6	84
70	Protein array technology to detect HER2 (erbB-2)-induced $\hat{\epsilon}$ cytokine signature $\hat{\epsilon}$ <sup>TM</sup> in breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 1117-1124.	1.3	83
71	Prediction of Extra Virgin Olive Oil Varieties through Their Phenolic Profile. Potential Cytotoxic Activity against Human Breast Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 9942-9955.	2.4	82
72	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006, 9, 346-357.	1.3	81

#	ARTICLE	IF	CITATIONS
73	Continuous administration of polyphenols from aqueous rooibos ( <i>Aspalathus linearis</i> ) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. <i>Phytomedicine</i> , 2011, 18, 414-424.	2.3	79
74	In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 1-4.	1.2	77
75	The mitochondrial H <sup>+</sup> -ATP synthase and the lipogenic switch. <i>Cell Cycle</i> , 2013, 12, 207-218.	1.3	77
76	Molecular Promiscuity of Plant Polyphenols in the Management of Age-Related Diseases: Far Beyond Their Antioxidant Properties. <i>Advances in Experimental Medicine and Biology</i> , 2014, 824, 141-159.	0.8	77
77	Mapping of the circulating metabolome reveals $\beta$ -ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. <i>International Journal of Obesity</i> , 2015, 39, 279-287.	1.6	77
78	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2 <sup>â€</sup> -O-Methylation of Viral RNA. <i>Viruses</i> , 2020, 12, 525.	1.5	75
79	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. <i>Scientific Reports</i> , 2013, 3, 2560.	1.6	74
80	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. <i>Oncotarget</i> , 2012, 3, 1600-1614.	0.8	73
81	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. <i>Medical Hypotheses</i> , 2005, 64, 997-1001.	0.8	72
82	Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response. <i>Cell Cycle</i> , 2011, 10, 1499-1501.	1.3	72
83	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004, 84, 183-195.	1.1	71
84	Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. <i>Molecular Carcinogenesis</i> , 2004, 41, 164-178.	1.3	71
85	AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. <i>Cell Cycle</i> , 2009, 8, 3679-3683.	1.3	70
86	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. <i>Oncolmmunology</i> , 2019, 8, e1633235.	2.1	70
87	Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. <i>Aging</i> , 2011, 3, 1063-1077.	1.4	70
88	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. <i>Aging</i> , 2016, 8, 1330-1352.	1.4	70
89	Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer Cells. <i>Breast Cancer Research and Treatment</i> , 2002, 72, 203-219.	1.1	68
90	Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression. <i>Journal of Clinical Oncology</i> , 2006, 24, 3735-3746.	0.8	68

#	ARTICLE	IF	CITATIONS
91	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. <i>Scientific Reports</i> , 2013, 3, 2459.	1.6	67
92	Fatty acid synthase regulates estrogen receptor- $\beta$ signaling in breast cancer cells. <i>Oncogenesis</i> , 2017, 6, e299-e299.	2.1	67
93	HER2 (erbB-2)-targeted effects of the $\omega$ -3 polyunsaturated. Fatty acid $\omega$ -linolenic acid (ALA; 18:3n-3) in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". <i>Clinical and Translational Oncology</i> , 2006, 8, 812-820.	1.2	66
94	Targeting fatty acid synthase: Potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. <i>Drug News and Perspectives</i> , 2005, 18, 375.	1.9	66
95	BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 157-163.	1.3	65
96	Stem cell-like ALDH <sup>bright</sup> cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. <i>Cell Cycle</i> , 2013, 12, 3390-3404.	1.3	65
97	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. <i>Medical Hypotheses</i> , 2005, 64, 342-349.	0.8	62
98	Lemon verbena ( <i>Lippia citriodora</i> ) polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms. <i>Phytomedicine</i> , 2015, 22, 605-614.	2.3	61
99	The nutritional phenome of EMT-induced cancer stem-like cells. <i>Oncotarget</i> , 2014, 5, 3970-3982.	0.8	61
100	Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical "translational research experience at the Catalan Institute of Oncology. <i>Annals of Oncology</i> , 2010, 21, 187-189.	0.6	60
101	Dynamic emergence of the mesenchymal CD44 <sup>pos</sup> CD24 <sup>neg</sup> /low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 27-33.	1.0	60
102	Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays. <i>International Journal of Molecular Medicine</i> , 2008, 22, 433-9.	1.8	60
103	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb <sup>®</sup> ). <i>Clinical and Translational Oncology</i> , 2009, 11, 455-459.	1.2	58
104	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. <i>Drug Resistance Updates</i> , 2011, 14, 212-223.	6.5	58
105	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. <i>Aging Cell</i> , 2018, 17, e12772.	3.0	58
106	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. <i>Cell Cycle</i> , 2014, 13, 1132-1144.	1.3	57
107	Gerosuppressant Metformin: less is more. <i>Aging</i> , 2011, 3, 348-362.	1.4	56
108	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. <i>Cell Cycle</i> , 2012, 11, 1235-1246.	1.3	56



#	ARTICLE	IF	CITATIONS
109	Mitotic kinase dynamics of the active form of AMPK (Phospho-AMPK $\pm$ Thr172) in human cancer cells. <i>Cell Cycle</i> , 2009, 8, 788-791.	1.3	55
110	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. <i>Scientific Reports</i> , 2012, 2, 964.	1.6	55
111	Multifunctional targets of dietary polyphenols in disease: A case for the chemokine network and energy metabolism. <i>Food and Chemical Toxicology</i> , 2013, 51, 267-279.	1.8	55
112	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. <i>Oncotarget</i> , 2018, 9, 35687-35704.	0.8	55
113	Genome-wide inhibitory impact of the AMPK activator metformin on [ <i>kinesins, tubulins, histones, auroras</i> and <i>polo-like kinases</i> ] M-phase cell cycle genes in human breast cancer cells. <i>Cell Cycle</i> , 2009, 8, 1633-1636.	1.3	54
114	Pediatric solid organ transplant recipients: Transition to home and chronic illness care. <i>Pediatric Transplantation</i> , 2015, 19, 118-129.	0.5	54
115	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. <i>Food and Chemical Toxicology</i> , 2013, 60, 360-368.	1.8	53
116	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. <i>Carcinogenesis</i> , 2018, 39, 601-613.	1.3	53
117	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. <i>Oncotarget</i> , 2015, 6, 12279-12296.	0.8	53
118	Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells. <i>Current Molecular Medicine</i> , 2010, 10, 674-691.	0.6	52
119	<i>Hibiscus sabdariffa</i> extract lowers blood pressure and improves endothelial function. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 1374-1378.	1.5	52
120	Silibinin is a direct inhibitor of STAT3. <i>Food and Chemical Toxicology</i> , 2018, 116, 161-172.	1.8	52
121	The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. <i>Annals of Oncology</i> , 2009, 20, 592-595.	0.6	50
122	Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. <i>Cell Cycle</i> , 2011, 10, 1295-1302.	1.3	50
123	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. <i>International Journal of Oncology</i> , 2012, 41, 1128-1138.	1.4	50
124	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in <i>ALK</i> -rearranged lung cancer. <i>Cell Cycle</i> , 2016, 15, 3413-3418.	1.3	49
125	Basal/HER2 breast carcinomas. <i>Cell Cycle</i> , 2013, 12, 225-245.	1.3	48
126	Structure-Activity Relationships of Extra-Virgin Olive Oil Phenolic Compounds: Health Properties and Bioavailability. <i>Antioxidants</i> , 2020, 9, 685.	2.2	48



#	ARTICLE	IF	CITATIONS
127	Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 125-137.	1.1	47
128	Extracellular Fatty Acid Synthase: A Possible Surrogate Biomarker of Insulin Resistance. <i>Diabetes</i> , 2010, 59, 1506-1511.	0.3	47
129	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. <i>Oncotarget</i> , 2016, 7, 32006-32014.	0.8	47
130	Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. <i>Oncology Reports</i> , 1994, 20, 1369.	1.2	46
131	Characterization of isomers of oleuropein aglycon in olive oils by rapid-resolution liquid chromatography coupled to electrospray time-of-flight and ion trap tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 51-59.	0.7	46
132	Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin). <i>International Journal of Oncology</i> , 2010, 37, 669-78.	1.4	46
133	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. <i>Biochemical and Biophysical Research Communications</i> , 2011, 407, 412-419.	1.0	44
134	Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 81-89.	1.5	43
135	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004, 11, 1241-52.	1.2	43
136	Tentative Characterization of Novel Phenolic Compounds in Extra Virgin Olive Oils by Rapid-Resolution Liquid Chromatography Coupled with Mass Spectrometry. <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 11140-11147.	2.4	42
137	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. <i>British Journal of Cancer</i> , 2012, 106, 1406-1414.	2.9	42
138	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1770.	1.0	42
139	Stem cell property epithelial-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbixá,®) efficacy in KRAS wild-type tumor cells. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 10-29.	1.2	41
140	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. <i>International Journal of Oncology</i> , 2004, 24, 591-608.	1.4	41
141	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. <i>Histology and Histopathology</i> , 2017, 32, 687-698.	0.5	40
142	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. <i>Oncotarget</i> , 2014, 5, 2344-2348.	0.8	40
143	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. <i>Oncotarget</i> , 2016, 7, 71151-71168.	0.8	40
144	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerbá®) in human breast carcinoma cells. <i>Annals of Oncology</i> , 2008, 19, 1097-1109.	0.6	39

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

145	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to		
-----	--	--	--

#	ARTICLE	IF	CITATIONS
163	Oncometabolic Nuclear Reprogramming of Cancer Stemness. <i>Stem Cell Reports</i> , 2016, 6, 273-283.	2.3	34
164	The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. <i>Oncology Reports</i> , 2011, 25, 135-40.	1.2	34
165	A bidirectional $\alpha 5 \beta 1$ integrin-ERK1/ERK2 MAPK connection regulates the proliferation of breast cancer cells. <i>Molecular Carcinogenesis</i> , 2006, 45, 795-804.	1.3	33
166	Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites. <i>Cell Cycle</i> , 2014, 13, 699-709.	1.3	33
167	Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. <i>Nutrients</i> , 2017, 9, 121.	1.7	33
168	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , 2021, 12, 977.	2.7	33
169	If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, e207-e209.	0.8	32
170	A $\mu$ -HPLC-CE platform coupled to ESI-TOF-MS to characterize the phenolic fraction in olive oil. <i>Electrophoresis</i> , 2009, 30, 2688-2701.	1.3	32
171	Thyroid hormone responsive Spot 14 increases during differentiation of human adipocytes and its expression is down-regulated in obese subjects. <i>International Journal of Obesity</i> , 2010, 34, 487-499.	1.6	32
172	Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). <i>Cell Cycle</i> , 2011, 10, 3140-3152.	1.3	32
173	The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism. <i>Nucleic Acids Research</i> , 2019, 47, 4240-4254.	6.5	32
174	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1606.	1.8	32
175	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa <sup>®</sup> )-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 0, , .	1.8	31
176	Up-regulation of $\alpha 5 \beta 1$ integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. <i>Differentiation</i> , 2007, 75, 819-830.	1.0	31
177	Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. <i>Oncoscience</i> , 2014, 1, 803-806.	0.9	31
178	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. <i>Oncotarget</i> , 2013, 4, 1484-1495.	0.8	31
179	The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptintm) in chemoresistant ovarian cancer cells. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 219-221.	1.2	30
180	Uptake and metabolism of olive oil polyphenols in human breast cancer cells using nano-liquid chromatography coupled to electrospray ionization-time of flight-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 898, 69-77.	1.2	30

#	ARTICLE	IF	CITATIONS
181	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. <i>Oncoscience</i> , 2016, 2, 958-967.	0.9	30
182	The tyrosine kinase receptor HER2 (c-erbB-2): From oncogenesis to adipogenesis. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 1147-1152.	1.2	29
183	Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. <i>Aging</i> , 2014, 6, 731-741.	1.4	29
184	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. <i>Oncology Reports</i> , 2004, 12, 411-22.	1.2	29
185	Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1? (HIF-1?) -related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 857-863.	1.2	28
186	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. <i>Journal of Cellular Physiology</i> , 2011, 226, 52-57.	2.0	28
187	Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. <i>International Journal of Oncology</i> , 2011, 38, 1533-47.	1.4	28
188	Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. <i>PLoS ONE</i> , 2015, 10, e0137800.	1.1	28
189	A multiscale model of epigenetic heterogeneity-driven cell fate decision-making. <i>PLoS Computational Biology</i> , 2019, 15, e1006592.	1.5	28
190	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 86, 102-104.	0.9	27
191	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. <i>Food and Chemical Toxicology</i> , 2016, 96, 191-204.	1.8	27
192	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. <i>Food and Chemical Toxicology</i> , 2019, 128, 35-45.	1.8	27
193	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. <i>International Journal of Oncology</i> , 2002, 21, 745.	1.4	26
194	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. <i>Nutrients</i> , 2019, 11, 1656.	1.7	26
195	Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "cestarvation" strategies in BRCA1 carriers. <i>Oncotarget</i> , 2016, 7, 52974-52992.	0.8	26
196	Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 157 but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. <i>International Journal of Oncology</i> , 2004, 24, 1369-83.	1.4	26
197	Metformin and Breast Cancer: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2705.	1.8	26
198	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. <i>Annals of Oncology</i> , 2004, 15, 1719-1721.	0.6	25

#	ARTICLE	IF	CITATIONS
199	The acute impact of polyphenols from <i>Hibiscus sabdariffa</i> in metabolic homeostasis: an approach combining metabolomics and gene-expression analyses. <i>Food and Function</i> , 2015, 6, 2957-2966.	2.1	25
200	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. <i>Cell Cycle</i> , 2015, 14, 3527-3532.	1.3	25
201	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. <i>Aging</i> , 2019, 11, 2874-2888.	1.4	25
202	Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors?. <i>Experimental Biology and Medicine</i> , 2005, 230, 151-154.	1.1	24
203	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007, 18, 973.	1.2	24
204	Energy Metabolism and Metabolic Sensors in Stem Cells: The Metabostem Crossroads of Aging and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014, 824, 117-140.	0.8	24
205	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of $\hat{3}$ -linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. <i>Medical Hypotheses</i> , 2005, 64, 337-341.	0.8	23
206	The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 638-643.	1.0	23
207	Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 49.	1.8	23
208	Stratification of cancer and diabetes based on circulating levels of formate and glucose. <i>Cancer &amp; Metabolism</i> , 2019, 7, 3.	2.4	23
209	Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model. <i>PLoS Computational Biology</i> , 2018, 14, e1006052.	1.5	23
210	$\gamma$ -6 Polyunsaturated fatty acid $\gamma$ -linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: $\gamma$ -Linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. <i>International Journal of Cancer</i> , 2004, 109, 949-954.	2.3	22
211	AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 488-493.	1.0	22
212	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. <i>Cancers</i> , 2021, 13, 1132.	1.7	22
213	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. <i>Anticancer Research</i> , 2014, 34, 4323-7.	0.5	21
214	Rejuvenating regeneration: Metformin activates endogenous adult stem cells. <i>Cell Cycle</i> , 2012, 11, 3521-3522.	1.3	20
215	Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 374-387.	1.9	20
216	One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. <i>Aging</i> , 2013, 4, 894-898.	1.4	20

#	ARTICLE	IF	CITATIONS
217	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2005, 15, 33-40.	1.8	20
218	Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. <i>Breast Cancer Research</i> , 2007, 9, 111.	2.2	19
219	<i>ATM</i> germline mutations in Spanish early-onset breast cancer patients negative for <i>BRCA1/BRCA2</i> mutations. <i>Clinical Genetics</i> , 2008, 73, 465-473.	1.0	19
220	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. <i>International Journal of Oncology</i> , 2009, 35, 1369-76.	1.4	19
221	Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis. <i>Journal of Clinical Virology</i> , 2011, 51, 199-201.	1.6	19
222	Metformin inhibits <i>RANKL</i> and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017, 16, 1022-1028.	1.3	19
223	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7661.	1.8	19
224	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprogramming in estrogen receptor-positive breast cancer. <i>Nature Communications</i> , 2021, 12, 1920.	5.8	19
225	The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. <i>Oncoscience</i> , 2016, 3, 242-257.	0.9	19
226	Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. <i>BMC Gastroenterology</i> , 2010, 10, 92.	0.8	18
227	Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis. <i>Cell Cycle</i> , 2012, 11, 4211-4221.	1.3	18
228	Managing Hypertension by Polyphenols. <i>Planta Medica</i> , 2015, 81, 624-629.	0.7	18
229	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2263.	1.8	18
230	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. <i>International Journal of Oncology</i> , 1992, 34, 43.	1.4	17
231	Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. <i>Clinical and Translational Oncology</i> , 2008, 10, 30-34.	1.2	17
232	Serine79-phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow. <i>Cell Cycle</i> , 2013, 12, 1639-1641.	1.3	17
233	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. <i>Frontiers in Oncology</i> , 2014, 4, 308.	1.3	17
234	Metformin targets histone acetylation in cancer-prone epithelial cells. <i>Cell Cycle</i> , 2016, 15, 3355-3361.	1.3	17

#	ARTICLE	IF	CITATIONS
235	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. <i>Frontiers in Oncology</i> , 2019, 9, 193.	1.3	17
236	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1757.	1.7	17
237	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015, 6, 7104-7122.	0.8	17
238	Î³-6 polyunsaturated fatty acid Î³-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004, 11, 1241.	1.2	16
239	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. <i>Molecular Genetics and Metabolism</i> , 2005, 84, 293-295.	0.5	16
240	Direct antitumour activity of zoledronic acid: preclinical and clinical data. <i>Clinical and Translational Oncology</i> , 2011, 13, 148-155.	1.2	16
241	Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance. <i>Cell Cycle</i> , 2012, 11, 2422-2426.	1.3	16
242	Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. <i>HIV Medicine</i> , 2013, 14, 233-240.	1.0	16
243	Revisiting silibinin as a novobiocin-like Hsp90 $\alpha$ -C-terminal inhibitor: Computational modeling and experimental validation. <i>Food and Chemical Toxicology</i> , 2019, 132, 110645.	1.8	16
244	Her-2/neu-induced "Cytokine Signature" in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 311-319.	0.8	16
245	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in <i>NRAS</i> -mutant metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 82185-82199.	0.8	16
246	The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs. <i>Current Pharmaceutical Design</i> , 2015, 21, 3644-3653.	0.9	16
247	Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity. <i>Biomolecules</i> , 2020, 10, 780.	1.8	16
248	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin $\text{®}$ ) by transcriptionally inhibiting "HER2 super-expression" occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. <i>International Journal of Oncology</i> , 2007, 31, 769.	1.4	15
249	Val1483Ile in <i>FASN</i> Gene Is Linked to Central Obesity and Insulin Sensitivity in Adult White Men. <i>Obesity</i> , 2009, 17, 1755-1761.	1.5	15
250	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbix $\text{Â$ ½) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. <i>International Journal of Oncology</i> , 2011, 39, 1455-79.	1.4	15
251	Mitostemness. <i>Cell Cycle</i> , 2018, 17, 918-926.	1.3	15
252	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. <i>Food and Chemical Toxicology</i> , 2019, 131, 110529.	1.8	15



#	ARTICLE	IF	CITATIONS
253	Metformin Is a Pyridoxal-5â€²-phosphate (PLP)-Competitive Inhibitor of SHMT2. <i>Cancers</i> , 2021, 13, 4009.	1.7	15
254	Metformin and cancer: <i>Quo vadis et cui bono?</i>. <i>Oncotarget</i> , 2016, 7, 54096-54101.	0.8	15
255	Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. <i>International Journal of Oncology</i> , 1992, 33, 1165.	1.4	14
256	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. <i>International Journal of Oncology</i> , 0, , .	1.4	14
257	Pharmacological Mimicking of Caloric Restriction Elicits Epigenetic Reprogramming of Differentiated Cells to Stem-Like Self-Renewal States. <i>Rejuvenation Research</i> , 2010, 13, 519-526.	0.9	14
258	Polyphenols in Olive Oil. , 2010, , 167-175.		14
259	Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes. <i>Cell Cycle</i> , 2014, 13, 358-370.	1.3	14
260	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting <sup>111</sup> In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. <i>Nuclear Medicine and Biology</i> , 2015, 42, 931-938.	0.3	14
261	Differential inhibitory effect of a pyrazolopyran compound on human serine hydroxymethyltransferase-amino acid complexes. <i>Archives of Biochemistry and Biophysics</i> , 2018, 653, 71-79.	1.4	14
262	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. <i>Carcinogenesis</i> , 2019, 40, 27-40.	1.3	14
263	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. <i>Pharmaceuticals</i> , 2021, 14, 559.	1.7	14
264	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. <i>Oncotarget</i> , 2014, 5, 1942-1954.	0.8	14
265	Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. <i>Nutrition and Metabolism</i> , 2010, 7, 14.	1.3	13
266	Identification of active compounds in vegetal extracts based on correlation between activity and HPLCâ€™MS data. <i>Food Chemistry</i> , 2013, 136, 392-399.	4.2	13
267	Ubiquitous Transgenic Overexpression of C-C Chemokine Ligand 2: A Model to Assess the Combined Effect of High Energy Intake and Continuous Low-Grade Inflammation. <i>Mediators of Inflammation</i> , 2013, 2013, 1-19.	1.4	13
268	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 33043-33049.	0.8	13
269	Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1555-1566.	1.8	13
270	Chemokine Câ€™C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice. <i>Scientific Reports</i> , 2020, 10, 11954.	1.6	13

#	ARTICLE	IF	CITATIONS
271	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. <i>International Journal of Oncology</i> , 2009, 34, 43-51.	1.4	13
272	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2005, 15, 33.	1.8	12
273	A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. <i>AIDS Research and Therapy</i> , 2013, 10, 11.	0.7	12
274	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 2180.	1.0	12
275	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017, 8, 35019-35032.	0.8	12
276	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. <i>Investigational New Drugs</i> , 2012, 30, 846-852.	1.2	11
277	Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities. <i>Vascular Medicine</i> , 2014, 19, 442-451.	0.8	11
278	CCN1 promotes vascular endothelial growth factor secretion through $\alpha_3\beta_1$ integrin receptors in breast cancer. <i>Journal of Cell Communication and Signaling</i> , 2014, 8, 23-27.	1.8	11
279	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. <i>Oncology Reports</i> , 2017, 38, 263-270.	1.2	11
280	Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. <i>Cytokine</i> , 2020, 126, 154923.	1.4	11
281	Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv090.	3.0	10
282	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. <i>Biomolecules</i> , 2021, 11, 473.	1.8	10
283	DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1081-7.	1.8	10
284	Fatty acid synthase: a druggable driver of breast cancer brain metastasis. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 427-444.	1.5	10
285	Expression status of the autophagy-regulatory gene <i>ATG6/BECN1</i> in <i>ERBB2</i> -positive breast carcinomas: Bypassing <i>ERBB2</i> -induced oncogenic senescence to regulate the efficacy of <i>ERBB2</i> -targeted therapies. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 284-290.	1.5	9
286	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017, 8, 99223-99236.	0.8	9
287	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. <i>Oncotarget</i> , 2016, 7, 11959-11971.	0.8	9
288	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. <i>International Journal of Oncology</i> , 2005, 26, 1507-15.	1.4	9

#	ARTICLE	IF	CITATIONS
289	Quantitative and functional influence of surround luminance on the letter contrast sensitivity function. <i>Ophthalmic and Physiological Optics</i> , 2010, 30, 188-199.	1.0	8
290	Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-12.	1.4	8
291	Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. <i>PLoS Computational Biology</i> , 2021, 17, e1008408.	1.5	8
292	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. <i>Cancers</i> , 2021, 13, 4168.	1.7	8
293	Heregulin, a new regulator of telomere length in human cells. <i>Oncotarget</i> , 2015, 6, 39422-39436.	0.8	8
294	Concentration, Propagation and Dilution of Toxic Gases in Underground Excavations under Different Ventilation Modes. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7092.	1.2	8
295	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1097-9.	1.4	7
296	Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease. <i>Journal of Vascular Surgery</i> , 2018, 68, 1135-1142.e6.	0.6	7
297	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. <i>International Journal of Oncology</i> , 2005, 26, 649-59.	1.4	7
298	Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3. <i>Journal of Clinical Oncology</i> , 2007, 25, 2496-2498.	0.8	6
299	Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 241-245.	1.1	6
300	Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 106-109.	0.8	6
301	Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection. <i>Medical Hypotheses</i> , 2013, 81, 125-130.	0.8	6
302	Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7737.	1.8	6
303	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioliomyomatosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13929.	3.3	6
304	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. <i>Aging</i> , 2020, 12, 24671-24692.	1.4	6
305	Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. <i>International Journal of Oncology</i> , 2010, 36, 107-15.	3.9	6
306	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. <i>International Journal of Oncology</i> , 2005, 26, 649.	1.4	5

#	ARTICLE	IF	CITATIONS
307	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. <i>International Journal of Oncology</i> , 2005, 26, 1507.	1.4	5
308	AMPK: A bona fide resident of the mitotic spindle midzone. <i>Cell Cycle</i> , 2012, 11, 841-842.	1.3	5
309	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. <i>Oncology Reports</i> , 2012, 27, 1887-92.	1.2	5
310	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 1067-1070.	0.7	5
311	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. <i>Frontiers in Oncology</i> , 2020, 10, 620641.	1.3	5
312	Systemic overexpression of C-C motif chemokine ligand 2 promotes metabolic dysregulation and premature death in mice with accelerated aging. <i>Aging</i> , 2020, 12, 20001-20023.	1.4	5
313	Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. <i>Oncotarget</i> , 2015, 6, 39408-39421.	0.8	5
314	DNA topoisomerase II $\pm$ (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: In vitro evidence for a functional amplicon $\text{\textcircled{TM}}$ involving FAS, Her-2/neu and TOP2A genes. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1081.	1.8	4
315	Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2013, 5, 459-462.	0.8	4
316	Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus. <i>Clinical and Translational Oncology</i> , 2015, 17, 581-589.	1.2	4
317	Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7830.	1.8	4
318	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib. <i>Breast Cancer Research</i> , 2011, 13, 401.	2.2	3
319	Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1160854.	0.3	3
320	TEMPORARY REMOVAL: Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression. <i>Journal of Hepatology</i> , 2021, , .	1.8	3
321	Polyphenols in olive oil: the importance of phenolic compounds in the chemical composition of olive oil. , 2021, , 111-122.		3
322	In silico clinical trials for anti-aging therapies. <i>Aging</i> , 2019, 11, 6591-6601.	1.4	3
323	Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin $\alpha 6 \beta 1$ drives endocrine resistance in breast cancer cells. <i>Aging</i> , 2022, 14, .	1.4	3
324	RESPONSE: Re: Effect of $\hat{1}^3$ -Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. <i>Journal of the National Cancer Institute</i> , 2006, 98, 718-720.	3.0	2

#	ARTICLE	IF	CITATIONS
325	Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the "self (stem cell)-seeding" nature of breast cancer disease?. Annals of Oncology, 2010, 21, 901-902.	0.6	2
326	An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients. Scientific Reports, 2015, 4, 5743.	1.6	2
327	Abstract 2746: Stat3 labels a subpopulation of reactive astrocytes required for brain metastasis. , 2019, , .		2
328	Treating atherosclerosis: targeting risk factors should not be the only option. Annals of Translational Medicine, 2018, 6, S34-S34.	0.7	2
329	The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?. Translational Cancer Research, 2017, 6, S201-S204.	0.4	2
330	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	1.4	2
331	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	1.7	2
332	Metformin and breast cancer: an opportunity for pharmacogenetics. Aging, 2022, 14, 5612-5613.	1.4	1
333	Growth and Molecular Interactions between Tamoxifen and Trastuzumab. Clinical Cancer Research, 2005, 11, 3597-3597.	3.2	0
334	Testing the Efficacy of Antiangiogenic Agents in Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 2007, 25, 2624-2624.	0.8	0
335	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 10, 219-226.	1.2	0
336	Metformin: a pharmacological approach integrating hyperinsulinemia breast cancer at the molecular, cellular clinical levels. Avances En Diabetologia, 2010, 26, 79-94.	0.1	0
337	Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.. American Journal of Cancer Research, 2022, 12, 839-851.	1.4	0